Navigation Links
Amarantus BioScience Reports Statistical Significance Achieved for MANF Striatal Reinnervation in Neurorestoration Animal Model of Parkinson's Disease
Date:2/4/2013

eutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.

MEDIA CONTACTS

Amarantus Bioscience, Inc.
pr@amarantus.com

Investor/Media Contact:
IR Sense, LLC

SOURCE Amarantus BioScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amarantus BioScience Launches New Website
2. Amarantus Bioscience Launches Online Corporate Communication Channels
3. Amarantus Bioscience to Present at OneMedForum 2013
4. Amarantus Appoints Super Bowl Champion Toi Cook to Board of Advisors to Advance TBI Program
5. Amarantus Completes Name Change and CUSIP Change
6. Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinsons Disease
7. Amarantus BioSciences Demands Cessation of Unauthorized Listing on Berlin-Bremen Stock Exchange
8. OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
9. Amarantus BioSciences Wins MANF Patent Challenge in Europe
10. Amarantus BioSciences Issues CEO Letter to Shareholders
11. Amarantus BioSciences Secures $1.1 Million in Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 2015 Research presented at the 2015 AACC ... the studies that led to a fingerprick Ebola test ... disease to receive approval from the World Health Organization ... grip on West Africa by ... workers to isolate and treat these patients much faster ...
(Date:7/27/2015)... , July 27, 2015 Junto Health, a ... share information and develop new technology solutions, today announced ... Group (SPG), a leader in health care policy consulting. ... engage in a collaborative innovation process while, at the ... trends in public policy, health care finance and the ...
(Date:7/25/2015)... ... , ... Technology leader Anton Paar offers the Abbemat ... temperature of the measuring prism. This is required to achieve the most precise ... key requirements. It is likely that no refractometer manufacturers on the market can ...
(Date:7/24/2015)... N.J. , July 24, 2015  Champions Oncology ... advanced technology solutions and services to personalize the development ... report its financial and operational results for the fourth ... on Tuesday, July 28, 2015, before market open. ... discuss the results that day at 9:00 a.m. EDT ...
Breaking Biology Technology:Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4It’s T-Time for Refractometers: On-site Temperature Check Now Available 2Champions Oncology to Announce Fourth Quarter Financial Results on Tuesday, July 28 2
... Dec. 14 The board of,directors of Abbott today declared ... marks the 336th consecutive quarterly dividend to be paid by,Abbott ... to,shareholders of record at the close of business on Jan. ... 35 consecutive years --,including a 10.2 percent increase earlier this ...
... (NYSE: BDY ) today announced its launch ... treatment of,external genital (EGW) and perianal warts (Condylomata ... is the first new,prescription treatment for external genital ... MediGene AG (Frankfurt: MDG) and has exclusive,marketing rights ...
... (NYSE:,FMC) and Pronova BioPharma ASA (OSE: PRON) ... worldwide license and development agreement to develop,products ... FMC. The,alginate-based capsule technology is expected to ... BioPharma,s products and has,the potential for use ...
Cached Biology Technology:Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 2Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 3Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 4Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 5Bradley Pharmaceuticals Launches Veregen(TM) (sinecatechins) Ointment, 15% 6FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 2FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 3FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products 4
(Date:6/25/2015)... 25, 2015  TAKE Solutions Ltd., a global business ... United States Patent and Trademark Office (USPTO) for its ... TAKE Solutions, Clinical Accelerators to reduce the time taken ... to standardization without the accelerators), thus reducing time to ... At the heart of the patented Clinical Data ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... April issue of the Journal of the American ... eating plans; dietary quality among children; and relationships between ... Increased Risk of Eating Disorders , While vegetarians tend ... non-vegetarians to be overweight or obese, they may be ...
... the Richard King Trainee Award. This award was instituted last ... to encourage ABMG trainees in their careers and to foster ... year the editorial board will review all articles published in ... or corresponding author during that year. The manuscript felt to ...
... Being able to accurately predict how a given ... non-responsive tumors the burden of undergoing toxic and ultimately ... a patient,s cancer-causing genetic lesions are contributing to drug ... Researchers led by Professor Scott Lowe, Ph.D., ...
Cached Biology News:News from the April 2009 Journal of the American Dietetic Association 2Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 2CSHL team develops mouse models of leukemia that predict response to chemotherapy 3CSHL team develops mouse models of leukemia that predict response to chemotherapy 4
Contained in EZ-Tn5™ Kits and are available separately for sequencing of an insertion site....
... peptide derived from the N-terminal region of ... Specificity: Specific for the N-terminus of the ... Dog Rat Mouse (positive controls: MDCK-II A431 ... heart blood vessel and brain mossy fiber ...
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Polyoxyethylene Lauryl Ether ... 0.02% Kathon Preservative. Surfactant. ... in immunohistochemistry is 1 ... 35 solution added to ...
Biology Products: